» Articles » PMID: 24246699

Genomic Characterization of Childhood Acute Lymphoblastic Leukemia

Overview
Journal Semin Hematol
Specialty Hematology
Date 2013 Nov 20
PMID 24246699
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and a leading case of childhood cancer death. The last decade has witnessed a transformation in our understanding of the genetic basis of ALL due to detailed integrative genomic profiling of large cohorts of childhood ALL. Initially using microarray based approaches, and more recently with next-generation sequencing, these studies have enabled more precise subclassification of ALL, and have shown that each ALL entity is characterized by constellations of structural and sequence mutations that typically perturb key cellular pathways including lymphoid development, cell cycle regulation, tumor suppression, Ras- and tyrosine kinase-driven signaling, and epigenetic regulation. Importantly, several of the newly identified genetic alterations have entered the clinic to improve diagnosis and risk stratification, and are being pursued as new targets for therapeutic intervention. Studies of ALL have also led the way in dissecting the subclonal heterogeneity of cancer, and have shown that individual patients commonly harbor multiple related but genetically distinct subclones, and that this genetically determined clonal heterogeneity is an important determinant of relapse. In addition, genome-wide profiling has identified inherited genetic variants that influence ALL risk. Ongoing studies are deploying detailed integrative genetic transcriptomic and epigenetic sequencing to comprehensively define the genomic landscape of ALL. This review describes the recent advances in our understanding of the genetics of ALL, with an emphasis on those alterations of key pathogenic or therapeutic importance.

Citing Articles

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Gupta S, Rau R, Kairalla J, Rabin K, Wang C, Angiolillo A N Engl J Med. 2024; 392(9):875-891.

PMID: 39651791 PMC: 11864901. DOI: 10.1056/NEJMoa2411680.


Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.

Alghandour R, Sakr D, Shaaban Y Ann Hematol. 2023; 102(6):1287-1300.

PMID: 37129698 PMC: 10181978. DOI: 10.1007/s00277-023-05241-2.


Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.

Ivanov A, Alecsa M, Popescu R, Starcea M, Mocanu A, Rusu C Int J Mol Sci. 2023; 24(5).

PMID: 36902091 PMC: 10003692. DOI: 10.3390/ijms24054661.


Recurrent Novel Translocations in B-Lymphoblastic Leukemia/Lymphoma.

Fang Y, Wang M, Hu S, Wang T, Liu Y, Xiao J Front Oncol. 2022; 12:896858.

PMID: 35912172 PMC: 9330356. DOI: 10.3389/fonc.2022.896858.


IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.

Das Gupta D, Paul C, Samel N, Bieringer M, Staudenraus D, Marini F Cell Death Differ. 2022; 29(11):2163-2176.

PMID: 35459909 PMC: 9613660. DOI: 10.1038/s41418-022-01005-z.


References
1.
Shah S, Schrader K, Waanders E, Timms A, Vijai J, Miething C . A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013; 45(10):1226-1231. PMC: 3919799. DOI: 10.1038/ng.2754. View

2.
Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, Benlasfer O . Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012; 2(1):e55. PMC: 3270253. DOI: 10.1038/bcj.2011.49. View

3.
Pui C, Campana D . Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia. Leukemia. 2007; 21(4):593-4. DOI: 10.1038/sj.leu.2404598. View

4.
Robinson H, Harrison C, Moorman A, Chudoba I, Strefford J . Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusion-bridge cycle. Genes Chromosomes Cancer. 2007; 46(4):318-26. DOI: 10.1002/gcc.20412. View

5.
Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M . Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013; 19(3):368-71. PMC: 3594483. DOI: 10.1038/nm.3078. View